T. Tada

Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection

This study demonstrates that AAV vectors expressing ACE2 decoy receptors can protect mice against SARS-CoV-2 infection, including recent Omicron subvariants, even when administered post-infection.

Prophylaxis and Treatment of SARS-CoV-2 infection by an ACE2 Receptor Decoy

This study demonstrates that an ACE2 receptor decoy protein effectively reduces SARS-CoV-2 virus loads in mice against both parental and Omicron variants.

Delta-Omicron recombinant escapes therapeutic antibody neutralization

This study identifies a Delta-Omicron recombinant SARS-CoV-2 variant that escapes Sotrovimab neutralization, highlighting the role of recombination in immune escape.

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies

This study evaluates the neutralization of SARS-CoV-2 Omicron BA.2 by therapeutic monoclonal antibodies, finding reduced neutralization by several antibodies but retention of activity by the AZD8895+AZD1061 cocktail.

Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies

The paper assesses Omicron's resistance to vaccine and monoclonal antibody neutralization, finding boosters improve efficacy but existing therapies are largely ineffective.

Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection

This study evaluates neutralization of SARS-CoV-2 Mu and C.1.2 variants by vaccine-elicited and convalescent antibodies, finding that vaccine-induced responses remain protective despite partial resistance.

Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens

This study shows that Alhydroxiquim-II-adjuvanted trimeric spike antigens induce high-titre, cross-variant neutralising antibodies against SARS-CoV-2 in animal models.

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

This study compares neutralizing antibody titers from mRNA and adenoviral vector vaccines against SARS-CoV-2 variants, finding lower neutralization against variants for Ad26.COV2.S and suggesting a second dose may improve protection.

Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection

This study examines inter-individual variability in SARS-CoV-2 infection of intestinal organoids, finding that ACE2 expression levels determine susceptibility and that Omicron variant shows higher infectivity.

SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum

This study assesses the neutralization efficacy of convalescent sera and mRNA vaccine-elicited antibodies against the SARS-CoV-2 lambda variant, finding minimal reduction in neutralizing titers.

SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta

This study investigates SARS-CoV-2 infection in placentas from infected pregnant women, finding that the virus infects syncytiotrophoblast cells and triggers maternal immune cell infiltration.

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.

This study evaluates the neutralization resistance of SARS-CoV-2 B.1.617 and B.1.618 spike proteins to vaccine-elicited and therapeutic antibodies, finding partial resistance due to specific mutations.

MARCH8 targets cytoplasmic lysine residues of various viral envelope glycoproteins

This study identifies MARCH8 as an antiviral factor that ubiquitinates and degrades viral envelope glycoproteins by targeting their cytoplasmic lysine residues.

B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies

The paper assesses neutralization of B.1.526 SARS-CoV-2 variants by vaccine-elicited and therapeutic antibodies, finding minimal impact on neutralizing titers.

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

This study evaluates the neutralization activity of two monoclonal antibodies against SARS-CoV-2 variants, finding reduced efficacy against B.1.351 and mink cluster 5 due to specific spike protein mutations.

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

This study evaluates the neutralizing activity of convalescent sera and BNT162b2 vaccine antibodies against SARS-CoV-2 variants, showing reduced efficacy against B.1.351 due to E484K mutation but overall maintained protection.

The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition

This study investigates antibody targeting of the ACE2-binding interface of SARS-CoV-2 Spike, finding that only a small fraction of RBD-binding antibodies target this region, suggesting it is less immunogenic.

A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture

The paper describes a modified soluble ACE2 protein that effectively inhibits SARS-CoV-2 infection in cell culture with higher potency than previous versions.

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.

The paper assesses neutralization capacity and antibody titers against SARS-CoV-2 antigens in recovered healthcare workers, finding that high titers of multiple isotypes correlate with neutralization.

MARCH8 inhibits viral infection by two different mechanisms

This study identifies two distinct mechanisms by which MARCH8 inhibits viral infection: ubiquitination of VSV-G and tyrosine motif-dependent sorting of HIV-1 Env.